In this episode of ATTD 2025 Conference Catch-Up, we dive into Adult Obesity: Causes, Risks, and Management Strategies, featuring insights on the SELECT trial, GLP-1 receptor agonists, and innovative approaches to managing obesity, Type 2 diabetes, and metabolic liver diseases. Join us as we summarize key takeaways from these thought-provoking presentations: Lessons from the SELECT Trial: Rethinking the Clinical Applications for the GLP-1RA Semaglutide – Prof. Donna Ryan Heterogeneity of Obesity and Type 2 Diabetes – Prof. Ewan Pearson Incretin-Based Therapies for the Treatment of Obesity-Related Diseases – Prof. Francesco Giorgino Prevalence and Rationale for New Terminologies in NAFLD – Dr. Samita Garg This episode is an essential listen for endocrinologists, diabetes specialists, obesity researchers, and healthcare professionals looking to stay informed about the latest therapeutic strategies for managing obesity and metabolic diseases, with a focus on clinical applications and emerging terminologies. Enjoy the listen! This podcast was created using AI to provide a quick and insightful summary of ATTD 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.  ATTD 2025, the 18th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on March 19-22, 2025, in Amsterdam. https://attd.kenes.com

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.